SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ida B. Wells Synthetic CCD

PatientIda B. Wells
Date of birth1957-07-16
IdentifiersMRN HR-ET022-SYN; SSN (made up) 000-22-5903
Document date2026-11-01
AuthorCordelia Ashworth-Banks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests. Concerns: She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normal; She wants to keep working and finish her memoir. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxenOne or two tablets up to three times a day as neededOral route2026-01-05activeS
Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route2026-01-20 to 2026-03-03completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-01-20activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet dailyOne tablet dailyOral route2026-01-20activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgeryOne tablet daily, with sick-day rulesOral route2026-02-03activeS
Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route2026-03-03activeS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram2026-01-05 to 2026-01-05completedS
Ultrasound of both kidneys and the bladder2026-01-20 to 2026-01-20completedS
Kidney diet session with the dietitian: sodium below 2 g a day, protein about 0.8 g per kg, plant-rich meals, no potassium restriction at present2026-02-03 to 2026-02-03completedS
Advance care planning conversation, about 25 minutes, including kidney treatment options2026-02-17 to 2026-02-17completedS

Immunizations

DateVaccineStatusEvidence
2026-01-20High-dose influenza vaccine, this seasoncompletedS
2026-01-20Pneumococcal conjugate vaccine PCV20completedS
2026-01-20Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-02-17Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-02-17Respiratory syncytial virus vaccine, adjuvanted (RSVPreF3), single dosecompletedS
2026-02-17Recombinant zoster vaccine, dose 1 of 2completedS
2026-03-03COVID-19 vaccine, mRNA, this seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

RelativeConditionAge at deathEvidence
fatherDied in the yellow fever epidemic when she was 16D (CLM-0002)
motherDied in the yellow fever epidemic when she was 16D (CLM-0002)
brotherAn infant brother died in the same yellow fever epidemicD (CLM-0002)

Health Concerns

ConcernStatusEvidence
She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normalactiveS
She wants to keep working and finish her memoiractiveS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-03; Potassium [Moles/volume] in Serum or Plasma 4.8 on 2026-03-03; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 2026-03-03; Urea nitrogen [Mass/volume] in Serum or Plasma 31 on 2026-03-03; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-01-05; Creatinine [Mass/volume] in Serum or Plasma 1.56 on 2026-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 36 on 2026-03-03; Cystatin C [Mass/volume] in Serum or Plasma 1.68 on 2026-01-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021)/1.73 sq M 38 on 2026-01-05; Albumin/Creatinine [Mass Ratio] in Urine 228 on 2026-01-20; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-01-05; Hemoglobin [Mass/volume] in Blood 11.2 on 2026-01-05; Ferritin [Mass/volume] in Serum or Plasma 168 on 2026-01-05; Iron saturation [Mass Fraction] in Serum or Plasma 24 on 2026-01-05; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-01-05; Phosphate [Mass/volume] in Serum or Plasma 3.8 on 2026-01-05; Parathyrin.intact [Mass/volume] in Serum or Plasma 84 on 2026-01-05; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 17 on 2026-01-05; Cholesterol [Mass/volume] in Serum or Plasma 214 on 2026-01-05; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 136 on 2026-01-05; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 2026-01-05; Triglyceride [Mass/volume] in Serum or Plasma 128 on 2026-01-05; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-01-05; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-01-05; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-02-17; Total score [Mini-Cog] 5 on 2026-02-17; Total score [AUDIT-C] 1 on 2026-02-17 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be establishedresolvedconfirmed R94.4S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney diseaseactiveconfirmed I12.9S — Synthetic modern diagnosis; no blood pressure from her life is recorded.
Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7%activeconfirmed N18.32S — Synthetic modern diagnosis linked to the kidney disease recorded at her death.
Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tirednessactiveconfirmed D63.1S — Synthetic laboratory finding.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normalactiveconfirmed E55.9S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-05Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-05Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-01-05Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/LKeep at 22 or above in kidney diseaseNormalS
2026-01-05Urea nitrogen [Mass/volume] in Serum or Plasma28mg/dL8-23 mg/dLHighS
2026-01-05Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-01-05Creatinine [Mass/volume] in Serum or Plasma1.42mg/dL0.59-1.04 mg/dLHighS
2026-01-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M40mL/min/{1.73_m2}60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4LowS
2026-01-05Cystatin C [Mass/volume] in Serum or Plasma1.68mg/L0.53-0.95 mg/LHighS
2026-01-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021)/1.73 sq M38mL/min/{1.73_m2}The confirmatory estimate KDIGO prefers when decisions depend on accuracy; 30 to 44 is G3bLowS
2026-01-05Albumin/Creatinine [Mass Ratio] in Urine240mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-01-05Hemoglobin A1c/Hemoglobin.total in Blood5.6%Below 5.7% is normal; 6.5% or higher is diabetesNormalS
2026-01-05Hemoglobin [Mass/volume] in Blood11.2g/dLAnemia in women is below 12.0 g/dLLowS
2026-01-05Ferritin [Mass/volume] in Serum or Plasma168ng/mL30-300 ng/mLNormalS
2026-01-05Iron saturation [Mass Fraction] in Serum or Plasma24%20-50%NormalS
2026-01-05Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-01-05Phosphate [Mass/volume] in Serum or Plasma3.8mg/dL2.5-4.5 mg/dLNormalS
2026-01-05Parathyrin.intact [Mass/volume] in Serum or Plasma84pg/mL15-65 pg/mLHighS
2026-01-0525-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma17ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientLowS
2026-01-05Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-01-05Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation136mg/dL<=99 mg/dLHighS
2026-01-05Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=50 mg/dLNormalS
2026-01-05Triglyceride [Mass/volume] in Serum or Plasma128mg/dL<=149 mg/dLNormalS
2026-01-05Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4.5 mIU/LNormalS
2026-01-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-01-20Albumin/Creatinine [Mass Ratio] in Urine228mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-02-03Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-02-03Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-02-03Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/LKeep at 22 or above in kidney diseaseNormalS
2026-02-03Urea nitrogen [Mass/volume] in Serum or Plasma30mg/dL8-23 mg/dLHighS
2026-02-03Creatinine [Mass/volume] in Serum or Plasma1.5mg/dL0.59-1.04 mg/dLHighS
2026-02-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M38mL/min/{1.73_m2}60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4LowS
2026-03-03Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-03Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-03-03Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/LKeep at 22 or above in kidney diseaseNormalS
2026-03-03Urea nitrogen [Mass/volume] in Serum or Plasma31mg/dL8-23 mg/dLHighS
2026-03-03Creatinine [Mass/volume] in Serum or Plasma1.56mg/dL0.59-1.04 mg/dLHighS
2026-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M36mL/min/{1.73_m2}60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4LowS
2026-02-17Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-02-17Total score [Mini-Cog]5{score}S
2026-02-17Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-05Body height157cmS
2026-01-05Body weight70.4kgS
2026-01-05Body mass index (BMI) [Ratio]28.6kg/m2S
2026-01-05Systolic blood pressure164mm[Hg]S
2026-01-05Diastolic blood pressure94mm[Hg]S
2026-01-05Heart rate78/minS
2026-01-05Respiratory rate16/minS
2026-01-05Body temperature36.6CelS
2026-01-05Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-01-20Body height157cmS
2026-01-20Body weight70kgS
2026-01-20Body mass index (BMI) [Ratio]28.4kg/m2S
2026-01-20Systolic blood pressure154mm[Hg]S
2026-01-20Diastolic blood pressure90mm[Hg]S
2026-01-20Heart rate76/minS
2026-01-20Respiratory rate16/minS
2026-01-20Body temperature36.7CelS
2026-01-20Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-02-03Body height157cmS
2026-02-03Body weight69.6kgS
2026-02-03Body mass index (BMI) [Ratio]28.2kg/m2S
2026-02-03Systolic blood pressure142mm[Hg]S
2026-02-03Diastolic blood pressure84mm[Hg]S
2026-02-03Heart rate74/minS
2026-02-03Respiratory rate16/minS
2026-02-03Body temperature36.6CelS
2026-02-03Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-02-17Body height157cmS
2026-02-17Body weight69.2kgS
2026-02-17Body mass index (BMI) [Ratio]28.1kg/m2S
2026-02-17Systolic blood pressure136mm[Hg]S
2026-02-17Diastolic blood pressure82mm[Hg]S
2026-02-17Heart rate72/minS
2026-02-17Respiratory rate16/minS
2026-02-17Body temperature36.6CelS
2026-02-17Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-03Body height157cmS
2026-03-03Body weight68.9kgS
2026-03-03Body mass index (BMI) [Ratio]28kg/m2S
2026-03-03Systolic blood pressure132mm[Hg]S
2026-03-03Diastolic blood pressure80mm[Hg]S
2026-03-03Heart rate72/minS
2026-03-03Respiratory rate16/minS
2026-03-03Body temperature36.6CelS
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-01-05New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone testsfinishedS
2026-01-20Two-week review of home blood pressure readings, the repeat urine test and the kidney ultrasound, with the nephrology consultationfinishedS
2026-02-03Two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozinfinishedS
2026-02-17Subsequent annual wellness visitfinishedS
2026-03-03Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months aheadfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counselingcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtaincompletedGL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021S
Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weekscompletedGL-AHA-HTN-2025, GL-KDIGO-BP-2021, GL-CMID-2026S
Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dyecompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baselinecompletedGL-KDIGO-CKD-2024, GL-KDIGO-MBD-2017, GL-CMID-2026S
Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9completedGL-CMID-2026, GL-AHA-HTN-2025, GL-USPSTF-DEP-2023S
On the nephrologist's advice: losartan 50 mg daily with potassium and creatinine in two weeks, then dapagliflozin 10 mg daily with a further check at two to four weeks, then losartan increased to the highest dose tolerated; sick-day rules for both; atorvastatin 20 mg; vitamin D3 1,000 units daily with PTH and vitamin D again at three months; blood pressure goal below 130/80 and a systolic below 120 if toleratedcompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-KDIGO-MBD-2017, GL-CMID-2026S
APOL1 genetic testing offered after counseling on what a result would and would not change, on privacy, and on what it could mean for relatives; her decision to defer recorded, with the offer left opencompletedGL-KDIGO-CKD-2024S
Kidney education session on the kidneys and the treatment options if they fail (transplant, home and center dialysis, and conservative kidney management), long before any decision is needed; kidney diet session with the dietitiancompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Vaccines for chronic kidney disease: high-dose influenza, PCV20 and two doses of HepB-CpG (she was not immune), then RSV, recombinant zoster and COVID-19, spaced at her requestcompletedGL-CDC-IMZ-2026S
Dapagliflozin 10 mg daily started now that potassium and creatinine are stable on losartancompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Losartan increased to 100 mg; potassium and creatinine in two to four weeks; urine albumin-to-creatinine ratio, hemoglobin, PTH and vitamin D at three months on treatment; nephrology review at three monthscompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated2026-03-03active132/80 in the clinic and 130/78 at home on losartan 50 mg and dapagliflozin; losartan increased to 100 mgS
Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment2026-03-03active240 and 228 mg/g at baseline; repeat due at three months on treatmentS
No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function2026-03-03completedNaproxen stopped at intake; acetaminophen used instead; medicines checked at every visitS
An informed decision about APOL1 genetic testing, made by her after counseling2026-01-20completedCounseled at the consultation; she chose to defer the test and may ask for it at any timeS
She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed2026-02-17completedKidney education session completed; wishes recorded at the annual wellness visitS

Functional Status

Mental Status